Zentalis Pharmaceuticals, Inc. announced on April 5, 2024, Melissa Epperly resigned as Treasurer, principal financial officer and principal accounting officer of Zentalis Pharmaceuticals, Inc., effective immediately. Effective on the Transition Date, the Company's Board of Directors appointed the Company's President, Cam Gallagher, as Treasurer and principal financial officer, and the Company's Vice President, Finance, Vincent Vultaggio, as interim principal accounting officer. Kyle Rasbach, the Company's Chief Business Officer, will oversee the Investor Relations function on an interim basis.

Mr. Gallagher, age 54, has served as the Company's President since May 2022 and as a member of the Board since the Company's founding in December 2014. Mr. Gallagher served as the Chief Business Officer at Immusoft Corp. (Immusoft) from April 2018 to May 2022, and as a member of Immusoft's Board of Directors from December 2022 to March 2024.

From October 2016 to June 2019, Mr. Gallagher served as the Head of Corporate Development and as a member of the Board of Directors of Oncternal Therapeutics, Inc. and from 2014 to 2016, he served as the Chief Business Officer and as a member of the Board of Directors of RetroSense Therapeutics, LLC, a gene therapy company, until its acquisition by Allergan plc. Mr. Gallagher also served as the Chief Business Officer of Kalyra Pharmaceuticals, Inc. from July 2013 to January 2024. Mr. Gallagher has been a member of the Board of Directors of Ocuphire Pharma, Inc. since November 2020 and currently serves as Chairman of the Board of Directors.

Mr. Gallagher has also served as a member of the Board of Directors of Healios K.K. from March 2022 to March 2023, as a member of the Board of Directors of selectION, Inc. since July 2018, as a managing member of Recurium IP Holdings, LLC (Recurium IP") since October 2017, and as managing director of Nerveda, LLC, a life science seed fund he co-founded, since September 2007. He also served as a member of the Board of Directors of Ray Therapeutics, Inc., a biotechnology company specializing in optogenetics gene therapies, from February 2021 to May 2023, and as a member of the Board of Directors of VelosBio Inc., an oncology-focused biopharmaceutical company, from December 2017 until its acquisition by Merck & Co., Inc. in December 2020. In addition, Mr. Gallagher has served on the Board of the Moores Cancer Center at UC San Diego Health since May 2019.

Mr. Gallagher received an M.B.A. from the University of San Diego and a B.S. in Business Administration from Ohio University. There is no arrangement or understanding between Mr. Gallagher and any other person, pursuant to which Mr. Gallagher was selected as interim Chief Financial Officer, Treasurer and principal financial officer. Mr. Vultaggio, age 41, has served as the Company's Vice President, Finance since February 2023 and has approximately 20 years of public accounting and corporate finance experience.

He joined Zentalis as Controller/Senior Director, Finance in January 2019 and was subsequently promoted to Executive Director, Finance and Controller in January 2021. Before joining the Company, Mr. Vultaggio was the Director of Accounting for Halozyme Therapeutics (Halozyme") from November 2015 to January 2019. Before joining Halozyme, Mr. Vultaggio held financial positions of varying levels of responsibility at life sciences and technology companies.

Mr. Vultaggio began his career as an auditor at Ernst & Young LLP from September 2004 through April 2011, where he last served as a Manager, Assurance Services. Mr. Vultaggio received a B.A. in Accountancy and an M.A. in Accountancy and Financial Management from the University of San Diego in 2004. There is no arrangement or understanding between Mr. Vultaggio and any other person, pursuant to which Mr. Vultaggio was selected as interim principal accounting officer.